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variants. SCC were all HPV negative, but had high mutation burden, with frequent abnormalities in TP53, PIK3CA and CDKN2A, at frequencies similar to lung SCC. Strikingly, 40% of the TP53 mutations were bi-allelic, which may be associated with improved outcome.
This is the first genomic analysis of these rare tumours. Our data suggest that patients with SCC arising in ovarian MCT could be included in any SCC-specific trial and may, like lung SCC, benefit from immune checkpoint inhibition.
Introduction
Mature cystic teratoma (MCT) of the ovary (also known as dermoid cyst and benign cystic teratoma) is a common benign gynaecological tumour, usually arising before the menopause (1) . The origin of MCT remains uncertain. Karyotype analyses suggested that there may be five separate types arising from different replication errors during meiosis (2) and that MCT may represent primary oocytes that have escaped from meiotic arrest (3) .
Because MCT contain all three germ cell layers, they often display multiple differentiated tissue types, including teeth, bone and hair. However, secondary transformation into invasive malignancy can also occur, at reported rates of 0.1 -1% (4, 5) . Up to 80% of these transformed teratomas contain squamous cell carcinoma (SCC), with the remaining 20% containing adenocarcinoma, thyroid carcinoma or carcinoid tumours (6) .
Due to their rarity, there are few large published series and no prospective clinical trials in MCT-derived SCC, and the recent Gynecologic Cancer Intergroup (GCIG) consensus review concluded that there were insufficient data to provide clear guidance on optimal treatment (7). However, the prognosis for these SCC is poor, especially for stage II -IV disease
[summarised in (6) ]. As a consequence, there is a need to characterise the genomic features of these tumours, to identify opportunities for patients to enrol in clinical trials.
Here we present analysis of the mutational state, copy number and zygosity of 151 cancer genes, as well as HPV status, in 25 cases of MCT with SCC from four large UK gynaecological cancer centres.
Patients and methods
Study conduct, survival analyses and patient samples DNA extraction and quantification.
DNA was extracted from 10 x 10 µm sections using QIAmp DNA FFPE Tissue Kit (Qiagen, UK) according to manufacturer's protocol. For macrodissected samples, paraffin was removed by the xylene/ethanol method. For microdissected samples, paraffin was removed by the heptane method. Briefly, 500 µl heptane was added to the sample, followed by 10 mins incubation at room temperature. 25 µl methanol was added, followed by centrifugation and aspiration. 1ml of absolute ethanol was then added to the pellet, followed by centrifugation and aspiration. The pellet was then air dried. From here the standard QIAmp extraction method was followed as per manufacturer's protocol. DNA was quantified on a A full description of mapping, QC, point mutation and indel calling, copy number calling (Table S2 ) and zygosity analysis is provided in Supplementary Methods.
Results

Patients and samples
Thirty-one cases were originally identified. Samples from three patients were missing.
There were low DNA yields (<50ng) in two cases, and sequencing failed in one SCC case, leaving 77 samples from 25 cases that were successfully sequenced ( Fig. 1 ; see Table S3 for QC). Twenty cases had sample trios (normal, MCT, SCC; Mutation and copy number analyses (Table S5 ).
The most commonly altered genes were TP53 (20/25 cases, 80%) ( (Table S6 ) and by point mutation (11/25 cases, 44%), a pattern similar to lung (8) and skin SCC (12) . Many SCCs showed evidence of highly rearranged genomes, with multiple low-level gains and losses (Fig. S2A ).
Amplification of MYC was called in two cases (SC005, SC021) (Table S6 ) and gain of MYC, falling just below the threshold for amplification calling, was seen in a further three cases (SC011, SC020, SC025), making the potential prevalence as high as 20% (5/25) (Fig. S2B ).
The only other recurrent amplification was JAK2 in two cases (SC020 and SC025) (Table   S6 ).
In five cases, there were two or more separate SCC samples. One of these (SC030) contained no detectable mutations, but in the remaining four cases, the TP53 mutation was an early and shared event, even in samples that showed some heterogeneity between samples (Table S6) . Two multi-sample cases (SC022, SC031) showed identical mutation profiles across samples, whilst the remaining two (SC014, SC025) showed some overlap:
SC014 shared two mutations (TP53, GNAQ) with PIK3CA and CDKN2A changes in one sample only. SC025 had four mutations in one sample and three in the second, but with only the TP53 variant being shared, and therefore the only one occurring prior to divergence of the two clones. Where there were multiple mutations in one gene (e.g. DDX3X in SC022;
APC in SC031), there was complete concordance between samples.
TP53 mutations showed a striking pattern with 8/20 (40%) mutated cases containing two or more variants ( Fig. 2A) . Several pieces of evidence suggested strongly that these abnormalities are bi-allelic rather than resulting from the presence of two or more discrete clonal populations or the existence of kataegis-like clusters. Firstly, in SC006 the mutations were sufficiently close to be phased, but were not detected in the same sequencing read pair and thus must lie on separate alleles (Fig S3A) . While the allele frequencies (18.4% and 13.1%) and copy number state (neutral, log 2 ratio shift of 0.05) do not preclude the possibility that these mutations are in separate clones, the heterogeneity analysis of the multi-region sampled SCCs shows that even where sub-clones are present, they share the same TP53 mutation (Table S7) . Secondly, high TP53 mutant allele frequencies in two cases can only be reconciled if the mutations are in the same cells. SC013 has TP53 mutation frequencies of 47.2% and 55.8%. If these mutations are in trans, they must account for 100% of TP53 alleles and thus cannot be in separate cells unless those cells are either homozygously mutated (and therefore bi-allelic for the same mutation) or have loss of the second copy to remove all wild-type alleles. However, the copy number state for TP53 in SC013 is a log 2 ratio shift of -0.35, which, at most, would indicate single-copy loss of TP53 in a fraction of cells. The possibility that these mutations are in cis cannot be excluded here. The same logic holds for SC021, which has TP53 mutation frequencies of 36.4% and 46.3% and a TP53 copy number log 2 ratio shift of 0.11, indicating no copy number alteration. Thirdly, two separate mutations were identified in SC005 at the same allele frequency at the same position (R280K at 21.4%, R280T at 22.9%), along with a third mutation (E285K) 14bp away that is in phase with the R280K mutation but always on a different allele to the R280T ( Fig S3) . There is a fourth, splice region TP53 mutation in this case that was too far away to phase with the other mutations. The copy number state for TP53 in this case again indicated no copy number alteration (log 2 ratio shift of 0.21). Possible explanations are therefore that there are two identically sized subclones, one of which has either one or two TP53 mutations and the other has either two or three, depending on how the distant mutation phases (although it is important to note that the three subclone explanation is not possible in the absence of copy number alteration). Alternatively, all TP53 mutations exist in the same cell with the splice mutation on the same allele as either the E285K/R280K or the R280T
mutations. The only explanation common to all three of the scenarios described above is that the TP53 mutations in these cases are bi-allelic.
There were other examples, albeit rare, of genes with multiple mutations, in a pattern consistent with an APOBEC signature (9) . Two samples (SC001 and SC005) had more than two TP53 mutations, SC022 had three mutations in DDX3X, SC002 had three PIK3CA mutations and SC009 had four mutations in NOTCH1. These clusters of mutations were mainly C>T (12/19) and C>G (4/19) but, in a TpC context rather than the CpG context that would indicate the ubiquitous cytosine deamination signature. However, numbers are small and sequencing of a larger genomic footprint would be required to capture enough mutations to carry out a formal signature analysis.
The PIK3CA alterations were canonical activating mutations, with the two most frequent mutations (p.E545K and p.E542K) corresponding to the two most frequent hotspots in COSMIC (Catalogue of Somatic Mutations in Cancer). CDKN2A was inactivated by a variety of mechanisms, the commonest being a large-scale deletion (8 cases), with nonsense mutation occurring in a single case and missense mutations in three cases. The missense mutations all occurred at mutation peaks in COSMIC, consistent with these events being under positive selective pressure and therefore inactivating.
Other recurrent changes included mutation of SMARCA4 and KMT2A (4 cases each), gain of MYC (3 cases) and gain of JAK2 (2 cases). Driver point mutations, as opposed to structural changes, in KMT2A are relatively rare, as evidenced by its point mutation profile in COSMIC, which shows a very low level of mutation spread evenly across the whole length of the gene. KMT2A has a relatively long coding sequence, making it more likely that mutations occur in it by chance. Given the size of our dataset we are unable to determine whether these KMT2A mutations are part of the so-called 'long tail' of driver mutations seen in many cancer types or if they represent the background mutation rate. The SMARCA4 mutations are likely passengers as none of them matched the five most recurrent variants in COSMIC. Mutations in BRCA1 and BRCA2 were identified in 2 cases each; all mutations were somatic missense alterations (Table S4) .
Clinical correlation
Follow up data were available on 23 cases. Twelve patients died and median overall survival was 20.1 months (Fig. 3A) , with no deaths occurring more than 24 months following diagnosis. The median follow-up for living patients was 55.8 months (range 6.8 -172.6 months) with 91% followed up for at least 41.6 months. As previously described, survival was significantly better for stage I compared to stage II-IV disease ( Fig. 3B ; HR = 0.301; p=0.021). There was no difference in survival based on age at diagnosis (Fig. 3C) , PIK3CA
or CDKN2A mutation status (Fig. S4A) , but there was a statistically significant association with TP53 mutation (HR = 0.178; p=0.002; Fig. 3D ). Exploratory analysis suggested that cases with bi-allelic TP53 mutations had significantly better overall survival than those with mono-allelic mutations (HR = 0.140; p=0.029; Fig. S4B ). The association of survival with stage and TP53 mutation status remained statistically significant (p=0.047 and p=0.011 respectively) in multivariate analysis (Table 2 ).
Zygosity analysis
In order to determine the stage of oogenesis that gave rise to the MCT, we analysed SNPs in the 151 sequenced genes for heterozygosity, and for a change in zygosity between normal tissue and MCT. All cases had some homozygous SNPs, but analysis of nonhomozygous SNPs revealed four groups (Table 3 , Fig. S5 ). Group A (10/21, 48%) showed the same levels of heterozygosity in normal and MCT, suggesting that they arise from cells prior to crossover (e.g. primordial germ cells or oogonia), whilst group B (3/21 cases, 14%)
showed substantially fewer heterozygous positions in the MCT compared to normal. This is consistent with development after prophase I in meiosis I, when chromosomal crossover Bi-allelic TP53 mutations have been identified in skin SCC (17) . Exome sequencing of eight skin SCC identified TP53 abnormalities in seven. Four of these showed LOH at chromosome 17p, but the 3 remaining cases lacked LOH and contained two or more distinct TP53 mutations, presumed to be biallelic. We are not aware of other descriptions of bi-allelic alterations in other SCC, nor of any previous potential correlation between bi-allelic TP53 mutations and improved outcome.
There remains considerable debate as to the origin of MCT. Originally thought to represent parthenogenic activation of oocytes (ie embryological development in the absence of a male gamete) at the end of meiosis I (18), cytogenetic analyses later suggested the existence of five separate MCT groups, arising from distinct stages of meiosis (2) . More recent short tandem repeat analyses generated conflicting data, supporting origins in oogonia (19) or primary oocytes that have escaped meiotic arrest (3).
Our study was not designed to identify cell of origin of MCT, but to analyse whether there were obvious SCC precursor mutations present in MCT. These we did not find -indeed, the MCT had few mutations or copy number alterations. However, we did identify four separate zygosity states in the 22 MCT samples from 21 cases. Groups A and B appear to have arisen primordial germ cells/oogonia and primary oocytes respectively. Group C contained some SNPs with altered allelic ratios. In the absence any detectable copy number alterations, one potential mechanism for generating such a state would be fusion of a cell that has undergone meiosis I but not completed meiosis II with a somatic cell, such that regions that had crossed over would end up in a 1:3 ratio while the rest of the genome would be 2:2. Alternatively this profile would be consistent with a mixture of a group B profile and contaminating normal cells. Group D, which lacked any SNPs in a 0.5:0.5 ratio but instead in each case showed a single allelic ratio consistent with a polyploid genome with unequal numbers of maternal and paternal chromosomes, may arise due to errors in meiosis I, when sets of homologous chromosomes should be separated. Given that only a single allelic ratio is present in these cells it seems unlikely that crossover has occurred. Analysis of any rare cancer is logistically problematic, and we acknowledge that there are potential shortcomings in our study. Identifying rare cancer samples is challenging, and we acquired the original 31 samples only by interrogating the archives of four large UK gynaecological cancer centres, with limited clinical data available. However, the clinical outcomes we describe are in line with a large systematic review (6), which suggests that our patients are broadly representative of this patient population. SCC arising within MCT has the added disadvantage that it is almost invariably an unexpected pathological diagnosis in an apparently benign tumour -there are no proven imaging characteristics to differentiate a benign MCT from one containing SCC (20, 21) . We therefore had to work with archival formalin-fixed paraffin-embedded material up to 17 years old. Finally, our sequencing panel, although containing 151 genes, did not cover the whole exome, and so there may be critical mutations that we have missed.
Despite these issues, this first systematic genomic evaluation of ovarian SCC arising in MCT shows clearly that they are similar to other non-HPV SCC, especially NSCLC, but with distinct features, including bi-allelic TP53 mutations. Further studies will be required to address the question of MCT cell of origin and to understand what triggers transformation of the MCT into SCC. However, our data suggest that patients with MCT-SCC could be included in trials of SCC-specific therapy and may, like lung SCC (22), derive benefit from immune checkpoint inhibition. Tables   Table 1 Summary Table 2 Multivariate analysis of overall survival. HR = Hazard Ratio; UL = Upper limit (95% confidence interval); LL = Lower limit (95% confidence interval) Table 3 Zygosity summary of the MCT samples. 
